Replies to post #292408 on Avid Bioservices Inc (CDMO)

[asmarterwookie]

The Yervoy Bavi was human trials.

Group A will enroll up to 16 patients to receive 2 weekly doses of bavituximab (3mg/kg) followed by combination therapy of ipilimumab (up to four cycles at 3mg/kg every 3 weeks) plus bavituximab (3mg/kg weekly for 12 weeks)

Group B will enroll up to 8 patients to receive standard ipilimumab alone (up to four cycles at 3mg/kg every 3 weeks)

Have not heard anything more about it have we?

The SOC changed during that time. Yes?

wook

[BioBS2012]

I doubt this study will provide anything more than something of scientific curiosity.

I will take this back. I just looked at the History of Changes on clinicaltrials.gov for this study and against an anticipated enrollment of 24, it shows actual enrollment was only THREE (3) patients !!!

NEVER going to hear this study mentioned by $PPHM again. ANYWHERE. EVER.

https://clinicaltrials.gov/archive/NCT01984255/2016_12_28/changes

Cheers. :-)